Abacus dx ASDG 2026
Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.
Abacus dx ASDG Interim Scientific Meeting 2026 Showcase
Abacus dx creates value by connecting innovative global suppliers with Australasian customers. We are proud to partner with leading suppliers like Asuragen, Biocartis, ImmunoIVD, Devyser, Invivoscribe, and ZytoVision by Zytomics to meet our customers’ needs.
We are exhibiting at the Australasian Society of Diagnostic Genomics (ASDG) Interim Scientific Meeting at the National Film & Sound Archive from 17 – 19 April.
Visit us at booth #4 to meet the team and discover more about our extensive range of specialised solutions.
Asuragen
Asuragen’s molecular assays are designed to provide streamlined workflow and ease of use and is comprised of two product portfolios; Genetics and Oncology. The genetics portfolio includes assays aiding in the detection of the FMR1 and C9orf72 gene, while the Oncology assays use molecular methods ranging from qPCR to NGS to assist our understanding of cancer.
Biocartis
Biocartis provides fully integrated and broadly applicable molecular diagnostics. The Idylla is Biocartis’ fully automated, real-time PCR-based molecular diagnostics system which provides fast access to highly reliable clinical molecular diagnostic information. The Idylla can detect BRAF V600E, E2, D, K, R and M mutations within 90 minutes.
Devyser
Devyser are specialists when it comes to complex DNA testing within hereditary diseases and oncology with products used to guide targeted cancer therapies and enable rapid prenatal diagnostics. Included in their portfolio is the BRCA NGS kit for detection of BRCA1 and BRCA2 in germline and somatic samples as well as the Fetal RHD kit used to determine fetal RHD status from maternal plasma.
Invivoscribe
Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation Research Use Only testing reagents and controls. They also provide CE-marked in vitro diagnostic products that are used to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative diseases.
ZytoVision
It all started with a vision: to develop and produce innovative in vitro diagnostic products, primarily for tumour diagnosis, based on the technique of in situ hybridization. That vision has since become a reality, and the name ZytoVision has been identified worldwide with technological and cost leadership in this field.
ZytoVision was founded in 2004 by Dr. Sven Hauke and Dr. Piere Marggraf-Rogalla and is located in Bremerhaven, Germany.